Genmab — Januar 2017
-
Man taler for tiden meget om i MM at individualisere behandlingen efter genetiske forudsætninger. Men der er ikke mindst tale om at stofferne har helt forskellige virkemåder. Nogle slår kræftcellerne ihjel, andre forsøger at overtale immunforsvaret til at gøre det. Og atter andre gør begge dele. Men i kombination gør de det bedst.
-
Tak for linket dohk - det lyder godt.
-
Under 5 milliarder USD i 2022 til Darzalex er alt for lavt. Jeg tror 5 milliarder nås allerede i 2020, og 8 milliarder i 2022.
-
Nyt studie i Myelodysplastisk syndrom https://www.clinicaltrials.gov/ct2/show/NCT03011034?term=daratumumab&rank=15
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind